Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 12:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 862 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Attention-Deficit Hyperactivity Disorder (ADHD) Clear all

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Not listed
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Cycling Exercise; Behavioral
Lead sponsor: Kent State University; Other
Eligibility: 18 Years to 26 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SHP465, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 41
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more

Conditions: Alcoholism, Attention Deficit Disorder
Interventions: Methylphenidate; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Little Rock, Arkansas • Irvine, California • Las Vegas, Nevada + 1 more

Conditions: Cocaine-Related Disorders, Substance-Related Disorders
Interventions: Methylphenidate; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1999
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sensory Processing Disorder, Autism Spectrum Disorder, ADHD
Interventions: aquatic occupational therapy; Other
Lead sponsor: Kristen Pataki; Other
Eligibility: 4 Years to 9 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Seven Hills, Ohio

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Smoking, ADHD
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: ADHD
Interventions: Vyvanse (lisdexamfetamine dimesylate), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 9
States / cities: Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more

Conditions: ADHD
Interventions: NRCT-101-SR, Placebo; Drug
Lead sponsor: Neurocentria, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more

Conditions: Adhd
Interventions: RELAX; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: ADZENYS XR-ODT, Placebo Oral Tablet; Drug
Lead sponsor: Aytu BioPharma, Inc.; Industry
Eligibility: 4 Years to 5 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Behavioral assessment and NAT EEG tests; Other
Lead sponsor: Think Now Incorporated; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Methylphenidate Hydrochloride Extended Release Capsule; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: ADHD
Interventions: Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: NAT electroencephalography (EEG) test; Other
Lead sponsor: Think Now Incorporated; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Berkeley, California • Los Angeles, California • Portland, Oregon

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: SMS Intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Booster Treatment, No-Booster, No intervention, Treatment As Usual; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 11 Years
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: ADHD
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Years to 18 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Behavioral contingency management, Tolerance training; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 8 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Not listed
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 2,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Wayne, Pennsylvania

Conditions: ADHD
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 11 Years to 15 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Atomoxetine, Buspirone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Orlando, Florida + 5 more

Search by objective public record fields.

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Effects of Exercise Intensity on ADHD Symptoms

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Treatment of Patients With Alcoholism and Attention Deficit Disorder

Safety and Efficacy of SPD465 in Adults With ADHD

Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

Pediatric Aquatic Occupational Therapy for Children With Sensory Processing Challenges

Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD

Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Improving Emotion Regulation in Adolescents With ADHD

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medication in Adults With ADHD in the Primary Care Setting

Resources to Enhance the Adjustment of Children (REACH)

Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth

Classroom-Level Intervention to Promote Peers' Acceptance of Children With Attention Deficit Hyperactivity Disorder (ADHD)

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Dynamic Relationships Between Estrogen Fluctuations, Sleep, and Psychiatric Complexity Among Adolescent Females With ADHD

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar